Privileged structures as leads in medicinal chemistry

Frontiers in Medicinal Chemistry

Volumn 5, Issue 1, 2010, Pages 381-422

  Costantino, Luca ^a   Barlocco, Daniela ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Benzodiazepines; Biphenyls; Carbohydrates; Drug discovery; Pirrolynones; Privileged structures

Indexed keywords

EID: 84880147352     PISSN: 15672042     EISSN: 18755763     Source Type: Book Series    
DOI: None     Document Type: Review

References (181)

1. Wermuth, C. Selective optimization of side activities: another way for drug discovery. J. Med. Chem., 2004, 47, 1303-1314.
2. Evans, B.E.; Rittle, K.E.; Bock, M.G.; DiPardo, R.M.; Freidinger, R.M.; Whitter, W.L.; Lundell, G.F.; Veber, D.F.; Anderson, P.S.; Chang, R.S.L.; Lotti, V.J.; Cerino, D.J.; Chen, T.B.; Kling, P.J.; Kunkel, K.A.; Springer, J.P.; Hirshfield, J. Methods for drug discovery: development of potent, selective, orally effective Cholecystokinin antagonists. J. Med. Chem., 1988, 31, 2235-2246.
3. Bleicher, K.H.; Nettekoven, M.; Peters, J.U.; Wyler, R. Lead generation: Showing the seeds for future success. Chimia, 2004, 58, 588-600.
4. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein coupled receptors. ChemBiochem., 2002, 3, 928-944.
5. DeSimone, R.W.; Currie, K.S.; Mitchell, S.A.; Darrow, J.W.; Pippin, D.A. Privileged structures: Applications in drug design. Comb. Chem. High Through. Screen., 2004, 7, 473-493.
6. Bemis, G.W.; Murcko, M.A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem., 1996, 39, 2887-2893.
7. Lowrie, J.F.; Delisle, R.K.; Hobbs, D.W.; Diller, D.J. The different strategies for designing GPCR and kinase targeted libraries. Comb. Chem. High Through. Screen., 2004, 7, 495-510.
8. Horton, D.A.; Bourne, G.T.; Smythe, M.L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev., 2003, 103, 893-930.
9. Patchett, A.A.; Nargund, R.P. Privileged structures: an update. Ann. Rep. Med. Chem., 2000, 35, 289-298.
10. Muller, G. Medicinal chemistry to target family-directed masterkeys. Drug Discov Today, 2003, 8, 681-691.
11. Poupaert, J.; Carato, P.; Colacillo, E. 2(3H)-benzoxazolone and bioisosters as "privileged scaffold" in the design of pharmacological probes. Curr. Med. Chem., 2005, 12, 877-885.
12. Boehm, H.-J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostreva, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization: a promising alternative to random screening. J. Med. Chem., 2000, 43, 2664-2674.
13. Bondensgaart, K.; Ankerson, M.; Thogersen, H.; Hansen, B.S.; Wulff, B.S.; Bywater, R.P. Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem., 2004, 47, 888-899.
14. Tyndall, J.D.A.; Pfeiffer, B.; Abbenante, G.; Fairlie, D.P. Over one hundred peptide-activated G protein coupled receptors recognize ligands with turn structure. Chem. Rev., 2005, 105, 793-826.
15. Ortholand, J.Y.; Ganesan, A. Natural products and combinatorial chemistry: back to the future. Curr. Opin. Chem. Biol., 2004, 8, 271-280.
16. Henkel, T.; Brunne, R.M.; Muller, H.; Reichel, F. Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew. Chem. Int. Engl., 1999, 38, 643-647.
17. Walsh, C.; Clardy, J. Lessons from natural molecules. Nature, 2004, 432, 829-837.
18. Feher, M.; Schmidt, J.M. Property distribution: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem. Inf. Comput. Sci., 2003, 43, 218-227.
19. Koch, M.A.; Shuffenhauer, A.; Scheck, M.; Wetzel, S.; Casaulta, M.; Odermatt, A.; Ertl, P.; Waldmann, H. Charting biologically relevant chemical space: a structural classification of natural products (SCONP). Proc. Natl. Acad Sci. USA, 2005, 102, 17272-17277.
20. Schuffenhauer, A.; Ertl, P.; Roggo, S.; Wetzel, S.; Koch, M.A.; Waldmann, H. The scaffold tree-Visualization of the scaffold universe by hierarchical scaffold classification. J. Chem. Inf. Model., 2007, 47, 47-58.
21. Koch, M.A.; Wittenberg, L.O.; Basu, S.; Jeyaraj, D.A.; Gourzoulidou, E.; Reinecke, K.; Odermatt, A.; Waldmann, H. Proc. Natl. Acad. Sci. USA, 2004, 101, 16721-16726.
22. Charette, B.D.; MacDonald, R.G.; Wetzel, S.; Berkowitz, D.B.; Waldmann, H. Protein structure similarity clustering: dynamic treatment of PDB structures facilitates clustering. Angew. Chem. Int. Engl., 2006, 45, 7766-7770.
23. Noren-Muller, A.; Reis-Correa, I.; Prinz, H.; Rosenbaum, C.; Saxena, K.; Schwalbe, H.J.; Vestweber, D.; Cagna, G.; Schunk, S.; Schwarz, O.; Schieve, H.; Waldmann, H. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Natl. Acad. Sci. USA, 2006, 103, 10606-10611.
24. Scheck, M.; Koch, M.A.; Waldmann, H. Synthesis of a dysidiolide-inspired compound library and discovery of acetylcholinesterase inhibitors based on protein structure similarity clustering (PSSC). Tetrahedron, 2008, 64, 4792-4802.
25. Chessari, G.; Woodhead, A.J. From fragment to clinical candidate-a historical perspective. Drug Discov. Today, 2009, 14, 668-675.
26. Erlanson, D.A.; McDowell, R.S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem., 2004, 47, 3463-3482.
27. Schnur, D.M.; Hermsmeier, M.A.; Tebben, A.J. Are target-family-privileged substructures truly privileged? J. Med. Chem., 2006, 49, 2000-2009.
28. Aronov, A.M.; McClain, B.; Moody, C.S.; Murcko, M.A. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. J. Med. Chem., 2008, 51, 1214-1222.
29. Lameijer, E.; Kok, J.N.; Back, T.; Ijzerman, A.P. Mining a chemical database for fragment co-occurrence: discovery of "Chemical Clichès". J. Chem. Inf. Model., 2007 46, 553-562.
30. Sutherland, J.J.; Higgs, R.E.; Watson, I.; Vieth, M. Chemical fragments as foundations for understanding target space and activity prediction. J. Med. Chem., 2008, 51, 2689-2700.
31. Lounkine, E.; Auer, J.; Bajorath, J. Formal concept analysis for the identification of molecular fragment combinations specific for active and highly potent compounds. J. Med. Chem., 2008, 51, 5342-5348.
32. Hu, Y.; Wassermann, A.M.; Lounkine, E.; Bajorath, J. Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families. J. Med. Chem., 2010, 53, 752-758.
33. Breinbauer, R.; Vetter, I.R.; Waldmann, H. From protein domains to drug candidates: Natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem. Int. Engl., 2002, 41, 2878-2890.
34. Koch, M.A.; Breinbauer, R.; Waldmann, H. Protein structure similarity as guiding principle for combinatorial library design. Biol. Chem., 2003, 384, 1265-1272.
35. Sebhat, I.K.; Martin, W.J.; Ye, Z.; Barakat, K.; Mosley, R.T.; Johnston, D.B.R.; Bakshi, R.; Palucki, B.; Weinberg, D.H.; MacNeil, T.; Kalyani, R.N.; Tang, R.; Stearns, R.A.; Miller, R.R.; Tanvakopoulos, C.; Strack, A.M.; McGowan, E.; Cashen, D.E.; Drisko, J.E.; Hom, G.J.; Howard, A.D.; MacIntyre, E.; van der Ploeg, L.H.T.; Patchett, A.A.; Nargund, R.P. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist J. Med. Chem., 2002, 45, 4589-4593.
36. Pontillo, J.; Tran, J.A.; Fleck, B.A.; Marinkovic, D.; Arellano, M.; Tucci, F.C.; Lanier, M.; Nelson, J.; Parker, J.; Saunders, J.; Murphy, B.; Foster, A.C.; Chen, C. Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett., 2004, 14, 5605-5609.
37. Fisher, M.J.; Backer, R.T.; Collado, I.; de Frutos, O.; Husain, S.; Hsiung, H.M.; Kuklish, S.L.; Mateo, A.I.; Mullaney, J.T.; Ornstein, P.L.; Paredes, C.G.; O'Brian, T.P.; Richardson, T.I.; Shah, J.; Zgombick, J.M.; Briner, K. Privileged structure based ligands for melanocortin receptors-substituted benzylic piperazine derivatives. Bioorg. Med. Chem. Lett., 2005, 15, 4973-4978.
38. Fisher, M.J.; Backer, R.T.; Husain, S.; Hsiung, H.M.; Mullaney, J.T.; O'Brian, T.P.; Ornstein, P.L.; Rothhaar, R.R.; Zgombick, J.M.; Briner, K. Privileged structure-based ligands for melanocortin receptorstetrahydroquinolines, indoles, and aminotetralines. Bioorg. Med. Chem. Lett., 2005, 15, 4459-4462.
39. Richardson, T.I.; Ornstein, P.L.; Briner, K.; Fisher, M.J.; Backer, R.T.; Biggers, K.; Clay, M.P.; Emmerson, P.J.; Hertel, L.W.; Hsiung, H.M.; Husain, S.; Kahl, S.D.; Lee, J.A.; Lindstrom, T.D.; Martinelli, M.J.; Mayer, J.P.; Mullaney, J.T.; O'Brien, T.P.; Pawlak, J.M.; Revell, K.D.; Shah, J.; Zgombick, J.M.; Herr, R.J.; Melekhov, A.; Sampson, P.B.; King, C.H.R. Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor. J. Med. Chem., 2004, 47, 744-755.
40. Kuklish, S.L.; Backer, R.T.; Briner, K.; Doecke, C.W.; Husain, S.; Mullaney, J.T.; Ornstein, P.L.; Zgombick, J.M.; O'Brien, T.P.; Fisher, M.J. Privileged structure based ligands for melanocortin receptors-4,4-disubstituted piperidine derivatives. Bioorg. Med. Chem. Lett., 2006, 16, 3843-3846.
41. Briner, K.; Collado, I.; Fisher, M.J.; Garcia-Paredes, C.; Husain, S.; Kuklish, S.L.; Mateo, A.I.; O'Brien, T.P.; Ornstein, P.L.; Zgombick, J.; de Frutos, O. Privileged structure based ligands for melanocortin 4-receptors-aliphatic piperazine derivatives. Bioorg. Med. Chem. Lett. 2006, 16, 3449-3453.
42. Stahl, P.; Kissau, L.; Mazitschek, R.; Giannis, A.; Waldmann, H. Natural product derived receptor tyrosine kinase inhibitors: identification of IGF-1R, Tie-2 and VEGFR-3 inhibitors. Angew. Chem. Int. Engl., 2002, 41, 1174-1178.
43. Chu, L.; Hutchins, J.E.; Weber, A.E.; Lo, J.L.; Yang, Y.T.; Cheng, K.; Smith, R.G.; Fisher, M.H.; Wyvratt, M.J.; Goulet, M.T. Initial structure-activity relationship of a novel class of nonpeptidyl GnRH receptor antagonists: 2-arylindoles. Bioorg. Med. Chem. Lett., 2001, 11, 509-513.
44. Chu, L.; Lo, J.L.; Yang, Y.T.; Cheng, K.; Smith, R.G.; Fisher, M.H.; Wyvratt, M.J.; Goulet, M.T. SAR studies of novel 5-substituted 2-arylindoles as nonpeptidyl GnRH receptor antagonists. Bioorg. Med. Chem. Lett., 2001, 11, 515-517.
45. Smith, A.L.; Stevenson, G.I.; Lewis, S.; Patel, S.; Castro, J.L. Solid-phase synthesis of 2,3-disubstituted indoles: discovery of a novel, high-affinity, selective h5-HT2A antagonist. Bioorg. Med. Chem. Lett., 2000, 10, 2693-2696.
46. Willoughby, C.A.; Hutchins, S.M.; Rosauer, K.G.; Dhar, M.J.; Chapman, K.T.; Chicchi, G.G.; Sadowski, S.; Weinberg, D.H.; Patel, S.; Malkowitz, L.; Di Salvo, J.; Pacholok, S.G.; Cheng, K. Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. Bioorg. Med. Chem. Lett., 2002, 12, 93-96.
47. Roher, S.P.; Birzin, E.T.; Mosley, R.T.; Berk, S.C.; Hutchins, S.M.; Shen, D.M.; Xiong, Y.X.; Hayes, E.C.; Parmar, R.M.; Foor, F.; Mitra, S.W.; Degrado, S.J.; Shu, M.; Klopp, J.M.; Cai, S.J.; Blake, A.; Chan, W.W.S.; Pasternak, A.; Yang, L.Y.; Patchett, A.A.; Smith, R.G.; Chapman, K.T.; Schaeffer, J.M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science, 1998, 282, 737-740.
48. Brown, F.J.; Andisik, D.W.; Bernstein, P.R.; Bryant, C.B.; Ceccarelli, C.; Damewood, J.R.; Edwards, P.D.; Earley, R.A.; Feeney, S.; Green, R.C.; Gomes, B.; Kosmider, B.J.; Krell, R.D.; Shaw, A.; Steelman, G.B.; Thomas, R.M.; Vacek, E.P.; Veale, C.A.; Tuthill, P.A.; Warner, P.; Williams, J.C.; Wolanin, D.J.; Woolson, S.A. Design of orally active, non-peptidic inhibitors of human leucocyte elastase. J. Med. Chem., 1994, 37, 1259-1261.
49. Bernstein, P.R.; Andisik, D.; Bradley, P.K.; Bryant, C.B.; Ceccarelli, C.; Damewood, J.R.; Earley, R.; Edwards, P.D.; Feeney, S.; Gomes, B.C.; Kosmider, B.J.; Steelman, G.B.; Thomas, R.M.; Vacek, E.P.; Veale, C.A.; Williams, J.C.; Wolanin, D.J.; Woolson, S.A. Nonpeptidic inhibitors of human leucocyte elastase. 3. Design, synthesis, X-rays crystallographic analysis, and structure-activity relationships for a series of orally active 3-amino-6-phenyl-2-pyridinyl trifluoromethyl ketones. J. Med. Chem., 1994, 37, 3313-3326.
50. Veale, C.A.; Bernstein, P.R.; Bryant, C.; Ceccarelli, C.; Damewood, J.R.; Earley, R.; Feeney, S.W.; Gomes, B.; Kosmider, B.J.; Steelman, G.B.; Thomas, R.M.; Vacek, E.P.; Williams, J.C.; Wolanin, D.J.; Woolson, S. Nonpeptidic inhibitors of human leukocyte elastase. 5: design, synthesis, and X-ray crystallography of a series of orally active 5-aminopyrimidin-6-one-containing trifluoromethylketones. J. Med. Chem., 1995, 38, 98-108.
51. Koch, M.A.; Waldmann, H. Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. Drug Discov Today, 2005, 10, 471-483.
52. Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors: from starfish oocytes to clinical trials. Acc. Chem. Res., 2003, 36, 417-425.
53. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J.J.; Donella-Deana, A.; Pinna, L.; Letham, D.S.; Kato, J.Y.; Detivaud, L.; Leclerc, S., Meijer, L. Inhibition of cyclin-dependent kinases by purine analogs. Eur. J. Biochem., 1994, 224, 771-786.
54. Armstrong, J.I.; Portley, A.R.; Chang, Y.T.; Nierengarten, D.M.; Cook, B.N.; Bowman, K.G.; Bishop, A.; Gray, N.S.; Shokat, K.M.; Schultz, P.G.; Bertozzi, C.R. Discovery of carbohydrate sulfotransferase inhibitors from a kinase-directed library. Angew. Chem. Int. Engl., 2000, 39, 1303-1306.
55. Verdugo, D.E.; Cancilla, M.T.; Ge, X.; Gray, N.S.; Chang, Y.T.; Schultz, P.G.; Negishi, M.; Leary, J.A.; Bertozzi, C.R. Discovery of estrogen sulfotransferase inhibitors from a purine library screen. J. Med. Chem., 2001, 44, 2683-2686.
56. Best, M.D.; Brick, A.; Chapman, E.; Lu, L.V.; Cheng, W.C.; Wong, C.H. Rapid discovery of potent sulfotransferase inhibitors by diversity-oriented reaction in microplates followed by in situ screening. ChemBiochem., 2004, 5, 811-819.
57. Hirschmann, R.; Ducry, L.; Smith, A.B. Development of an efficient, region-and stereoselective route to libraries based on the ll-D-glucose scaffold. J. Org. Chem., 2000, 65, 8307-8316.
58. Liu, J.; Underwood, D.J.; Cascieri, M.A.; Rohrer, S.P.; Cantin, L.D.; Chicchi, G.; Smith, A.B.; Hirschmann, R. Synthesis, of a Substance P antagonist with a Somatostatin scaffold: factors affecting agonism/antagonism at the GPCRs and the role of pseudosymmetry. J. Med. Chem., 2000, 53, 3827-3831.
59. Hirschmann, R.; Nicolaou, K.C.; Pietranico, S.; Leahy, E.N.M.; Salvino, J.; Arison, B.; Cichy, M.A.; Spoors, P.G.; Shakespeare, W.C.; Sprengeler, P.A.; Hamley, P.; Smith, A.B.; Reisine, T.; Raynor, K.; Maechler, L.; Donaldson, C.; Vale, W.; Freidinger, R.M.; Cascieri, M.R.; Strader, C.D. De novo design and synthesis of Somatostatin non-peptide peptidomimetics utilizing oo-D-glucose as a novel scaffold. J. Am. Chem. Soc., 1993, 115, 12550-12568.
60. Hirschmann, R.; Hynes, J.; Cichy-Knight, M.A.; van Rijn, R.D.; Sprengeler, P.A.; Spoors, P.G.; Shakespeare, W.C.; Pietranico-Cole, S.; Barbosa, J.; Liu, J.; Yao, W.; Rohrer, S.; Smith, A.B. Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a mean to structural and biological diversity: a new route to ether synthesis. J. Med. Chem., 1998, 41, 1382-1391.
61. Hirschmann, R.; Nicolaou, K.C.; Pietranico S.; Savino, J.; Leahy, E.M.; Sprengler, P.A.; Furst, G.; Smith, A.B.; Strader, C.D.; Cascieri, M.A.; Candelore, M.R.; Donaldson, C.; Vale, W.; Maechler, L. Nonpeptidal peptidomimetics with pp-D-glucose scaffolding. A partial Somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist. J. Am. Chem. Soc., 1992, 114, 9217-9218.
62. Smith, A.B.; Cho, Y.S.; Pettit, G.R.; Hirschmann, R. Design, synthesis, and evaluation of azepine-based cryptophycin mimetics. Tetrahedron, 2003, 59, 6991-7009.
63. Prasad, V.; Birzin, E.T.; McVaugh, C.T.; van Rijn, R.D.; Roher, S.P.; Chicchi, G.; Underwood, D.J.; Thornton, E.R.; Smith, A.B.; Hirschmann, R. Effects of heterocyclic aromatic substituents on binding affinities at two distinct sites of Somatostatin receptors. Correlation with the electrostatic potential of the substituents. J. Med. Chem., 2003, 46, 1858-1869.
64. Angeles, A.R.; Neagu, I.; Birzin, E.T.; Thornton, E.R.; Smith, A.B.; Hirschmann, R. Synthesis and binding affinities of novel SRIF-mimiking aa-D-glucosides satisfying the requirement for a---cloud at C1. Org. Lett., 2005, 7, 1121-1124.
65. Hirschmann, R.F.; Nicolaou, K.C.; Angeles, A.R.; Chen, J.S.; Smith, A.B. The α-D-glucose scaffold as---turn mimetic. Acc. Chem. Res., 2009, 42, 1511-1520.
66. Mowery, B.P.; Prasad, V.; Kenesky, C.S.; Angeles, A.R.; Taylor, L.L.; Feng, J.J.; Chen, W.L.; Lin, A.; Cheng, F.C.; Smith, A.B.; Hirschmann, R. Catechol: a minimal scaffold for non-peptide peptidomimetics of the i + 1 and i + 2 positions of the ++-turn of somatostatin. Org. Lett., 2006, 8, 4397-4400.
67. Dinh, T.Q.; Smith, C.D.; Du, X.; Armstrong, R.W. Design, synthesis, and evaluation of the multidrug resistance-reversing activity of D-glucose mimetics of Hapalosin. J. Med. Chem., 1998, 41, 981-987.
68. Murphy, P.V.; O'Brien, J.L.; Gorey-Feret, L.J.; Smith, A.B. Structure-based design and synthesis of HIVprotease inhibitors employing beta-D-mannopyranoside scaffolds. Bioorg. Med. Chem. Lett., 2002, 12, 1763-1766.
69. Boer, J.; Gottschling, D.; Schuster, A.; Holzmann, B.; Kessler, H. Design, synthesis, and biological evaluation of ee4441 integrin antagonists based on 11-D-mannose as rigid scaffold. Angew. Chem. Int. Engl., 2001, 40, 3870-3873.
70. Wessel, H.P.; Banner, D.; Gubernator, K.; Hilpert, K.; Muller, K.; Tschopp, T. 6-Guanidinopyranoses: novel carbohydrate-based peptidomimetics. Angew. Chem. Iint. Ed., 1997, 36, 751-752.
71. Chakraborty, T.K.; Ghosh, S.; Jayaprakash, S.; Sharma, J.A.R.P.; Ravikanth, V.; Diwan, P.V.; Nagaraj, R.; Kunwar, A.C. Synthesis and conformational studies of peptidomimetics containing furanoid sugar amino acids as a sugar diacid. J. Org. Chem., 2000, 65, 6441-6457.
72. Lohof, E.; Planker, E.; Mang, C.; Burkhart, F.; Dechantsreiter, M.A.; Haubner, R.; Wester, H.J.; Schwaiger, M.; Holzemann, G.; Goodman, S.L.; Kessler, H. Carbohydrate derivatives for use in drug design: cyclic ddv-selective RGD peptides. Angew. Chem. Int. Engl., 2000, 39, 2761-2764.
73. Overkleeft, H.S.; Verhelst, S.H.L.; Pieterman, E.; Meeuwenoord, N.J.; Overhand, M.; Cohen, L.H.; van der Marel, G.A.; van Boom, J.H. Design and synthesis of a protein:farnesyltransferase inhibitor based on sugar amino acids. Tetrahedron Lett., 1999, 40, 4103-4106.
74. Smith, A.B.; Sasho, S.; Barwis, B.A.; Sprengeler, P.; Barbosa, J.; Hirschmann, R.; Cooperman, B.S. Design and synthesis of a tetrahydropyran-based inhibitor of mammalian ribonucleotide reductase. Bioorg. Med. Chem., 1998, 8, 3133-3136.
75. von Roedern, E.G.; Kessler, H. Sugar amino acids as a novel peptide mimetic. Angew. Chem. Int. Engl., 1994, 33, 687-689.
76. Miller, W.H.; Keenan, R.M.; Willette, R.N.; Lark, M.W. Identification and in vivo efficacy of smallmolecule antagonists of integrin aavvv3 (the vitronectin receptor). Drug Discov Today, 2000, 5, 397-408.
77. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the ssvvv3 integrin for a new cancer therapy. Angew. Chem. Int. Engl., 1997, 36, 1374-1389.
78. Pfaff, M.; Tangemann, K.; Muller, B.; Gurrath, M.; Muller, G.; Kessler, H.; Timpl, R.; Engel, J. Selective recognition of cyclic RGD peptides of NMR defined conformation by ttvIIvv3, 33vvv3, and 335551 integrins. J. Biol. Chem. 1994, 269, 20233-20238.
79. Bach, A.C.; Espina, R.; Jackson, S.A.; Stouten, P.F.W.; Duke, J.L.; Mousa, S.A.; DeGrado, W.F. Type II' to type I tt-turn swap changes specificity for integrins. J. Am. Chem. Soc., 1996, 118, 293-294.
80. van Well, R.M.; Overkleeft, H.S.; van der Marel, G.A.; Bruss, D.; Thibault, G.; de Groot, P.G.; van Boom, J.H.; Overhand, M. Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 331-334.
81. Dechantstreiter, M.A.; Planker, E.; Matha, B.; Lohof, E.; Holzemann, G.; Jonczyk, A.; Goodman, S.L.; Kessler, H. N-methylated cyclic RGD peptides as highly active and selective vvv3 integrin antagonists. J. Med. Chem., 1999, 42, 3033-3040.
82. Lohof, E.; Planker, E.; Mang, C.; Burkhart, F.; Dechantsreiter, M.A.; Haubner, R.; Wester, H.J.; Schwaiger, M.; Holzemann, G.; Goodman, S.L.; Kessler, H. Carbohydrate derivatives for use in drug design: Cyclic ddv-selective RGD peptides. Angew. Chem. Int. Engl., 2000, 39, 2761-2764.
83. Abrous, L.; Jokiel, P.A.; Friedrich, S.R.; Hynes, J.; Smith, A.B.; Hirschmann, R. Novel chimeric scaffolds to extend the exploration of receptor space: Hybrid tt-D-glucose benzoheterodiazepine structures for broad screening. Effect of amide alkylation on the course of cyclization reactions. J. Org. Chem., 2004, 69, 280-302.
84. Abrous, L.; Hynes, J.; Friedrich, S.R.; Smith, A.B.; Hirschmann, R. Novel scaffolds for drug discovery: hybrids of hh-D-glucose with 1,2,3,4-tetrahydrobenzo[e][1,4]diazepin-5-one, the corresponding 1-oxazepine, and 2-and 4-pyridyldiazepines. Org. Lett., 2001, 3, 1089-1092.
85. Hajduk, P.; Bures, M.; Praestgaard, J.; Fesik, S.W. Privileged molecules for protein binding identified from NMR-based screening. J. Med. Chem., 2000, 43, 3443-3447.
86. Lam, P.Y.S.; Adams, J.J.; Clark, C.G.; Calhoun, J.; Luettgen, J.M.; Knabb, R.M.; Wexler, R.R. Discovery of 3-amino-4-chlorophenyl P1 as a novel and potent benzamidine mimic via sold-phase synthesis of an isoxazoline library. Bioorg. Med. Chem. Lett., 2003, 13, 1795-1799.
87. Faghih, R.; Dwight, W.; Pan, J.B.; Fox, G.B.; Krueger, K.M.; Esbenshade, T.A.; McVey, J.M.; Marsh, K.; Bennan, Y.L.; Hancock, A.A. Synthesis and SAR of aminoalkyl-biaryl-4-carboxamides: Novel and selective histamine H3 receptor antagonists. Bioorg. Med. Chem., 2003, 13, 1325-1328.
88. Guo, T.; Adang, A.E.P.; Dolle, R.E.; Dong, G.; Fitzpatrick, D.; Geng, P.; Ho, K.-K.; Kultgen, S.G.; Liu, R.; McDonald, E.; McGuinnes, B.F.; Saionz, K.W.; Valenzano, K.J.; van Straten, N.C.R.; Xie, D.; Webb, M.L. Small molecule biaryl FSH receptor agonists. Part 1: lead discovery via encoded combinatorial synthesis. Bioorg. Med. Chem. Lett., 2004, 14, 1713-1716.
89. Look, G.C.; Vacin, C.; Dias, T.M.; Ho, S.; Tran, T.H.; Lee, L.L.; Wiesner, C.; Fang, F.; Marra, A.; Westmacott, D.; Hromockyi, A.E.; Murphy, M.M.; Schullek, J.R. The discovery of biaryl acids and amides exhibiting abntibacterial activity against gram-positive bacteria. Bioorg. Med. Chem. Lett., 2004, 14, 1423-1426.
90. Stein, P.D.; Hunt, J.T.; Floyd, D.M.; Moreland, S.; Dickinson, K.E.J.; Mitchell, C.; Liu, E.C.K.; Webb, M.L.; Murugesan, N.; Dickey, J.; McMullen, D.; Zhang, R.; Lee, V.G.; Serdino, R.; Delaney, C.; Schaeffer, T.R.; Kozlowski, M. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-mnaphtalenesulfonamide. J. Med. Chem., 1994, 37, 329-331.
91. Murugesan, N.; Gu, Z.; Spergel, S.; Young, M.; Chen, P.; Mathur, A.; Leith, L.; Hermsmeier, M.; Liu, E.C.K.; Zhang, R.; Bird, E.; Waldron, T.; Marino, A.; Koplowitz, B.; Humphreyes, W.G.; Chong, S.; Morrison, R.A.; Webb, M.L.; Moreland, S.; Trippodo, N.; Barrish, J.C. Biphenylsulfonamide endothelin receptor antagonists. 4. discovery of N-[2'-[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl) [1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active EtA selective antagonist. J. Med. Chem., 2003, 46, 125-137.
92. Whittaker, M.; Floyd, C.D.; Brown, P.; Gearing, A.J.H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev., 1999, 99, 2735-2776.
93. Mah, R.; Gerspacher, M.; von Sprecher, A.; Stutz, S.; Tschinke, V.; Anderson, G.P.; Bertrand, C.; Subramanian, N.; Ball, H.A. Biphenyl derivatives as novel dual NK1/NK2-receptor antagonists. Bioorg. Med. Chem. Lett., 2002, 12, 2065-2068.
94. Loughlin, W.A.; Tyndall, J.D.A.; Glenn, M.P.; Fairlie, D.P. Beta-strand mimetics. Chem. Rev., 2004, 104, 6085-6117.
95. Tyndall, J.D.A.; Nall, T.; Fairlie, D.P. Proteases universally recognize beta strands in their active sites. Chem Rev., 2005, 105, 973-999.
96. Qian, Y.; Vogt, A.; Sebti, S.M.; Hamilton, A.D. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors. J. Med. Chem., 1996, 39, 217-223.
97. Maignan, S.; Guilloteau, J.P.; Pouzieux, S.; Choi-Sledeski, Y.M.; Becker, M.R.; Klein, S.I.; Ewing, W.R.; Pauls, H.W.; Spada, A.P.; Mikol, V. Crystal structures of human factor Xa complexed with potent inhibitors. J. Med. Chem., 2000, 43, 3226-3232.
98. Castanedo, G.M.; Sailes, F.C.; Dubree, N.J.P.; Nicholas, J.B.; Caris, L.; Clark, K.; Keating, S.M.; Beresini, M.H.; Chiu, H.; Fong, S.; Marters, J.C.; Jackson, D.Y.; Sutherlin, D.P. Solid-phase synthesis of dual dd4441/114447 integrin antagonists: two scaffolds with overlapping pharmacophores. Bioorg. Med. Chem. Lett., 2002, 12, 2913-2917.
99. Jacoby, E. Biphenyls as potential mimetics of protein α-helix. Bioorg. Med. Chem. Lett., 2002, 12, 891-893.
100. Orner, B.P.; Ernst, J.T.; Hamilton, A.D. Toward proteomimetics: Terpenyl derivatives as structural and functional mimics of extended regions of an ff-helix. J. Am. Chem. Soc., 2001, 123, 5382-5383.
101. Kutzki, O.; Park, H.S.; Ernst, J.T.; Orner, B.P.; Yin, H.; Hamilton, A.D. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J. Am. Chem. Soc., 2002, 124, 11838-11839.
102. Yin, H.; Lee, G.; Parks, H.S.; Payne, G.A.; Rodriguez, J.A.; Sebti, S.M.; Hamilton, A.D. Terpenyl-based helical mimetics that disrupt the p53-hdm2 interaction. Angew. Chem. Int. Ed. Engl., 2005, 117, 2704-2707.
103. Saraogi, I.; Hamilton, D. Alpha-helix mimetics as inhibitors of protein-protein interactions. Biochem. Soc. Trans., 2008, 36, 1414-1417.
104. Rodriguez, J.M.; Nevola, L.; Ross, N.T.; Lee, G.I.; Hamilton, A.D. ChemBioChem., 2009, 10, 829-833.
105. Muller, G.; Hessler, G.; Decornez, H.Y. Are 00-turn mimetics mimics of---turns? Angew. Chem. Int. Engl., 2000, 39, 894-896.
106. Suich, D.J.; Mousa, S.A.; Singh, G.; Liapakis, G.; Reisine, T.; DeGrado, W.F. Template-constrained cyclic peptide analogues of somatostatin: subtype selective binding to somatostatin receptors and antiangiogenic activity. Bioorg. Med. Chem., 2000, 8, 2229-2241.
107. Urbahns, K.; Harter, M.; Vaupel, A.; Albers, M.; Schmidt, D.; Bruggemeier, U.; Stelte-Ludwig, B.; Gerdes, C.; Tsujishita, H. Biphenyls as potent vitronectin receptor antagonists. Part 2: Biphenylalanine ureas. Bioorg. Med. Chem. Lett., 2003, 13, 1071-1074.
108. Urbahns, K.; Harter, M.; Albers, M.; Schmidt, D.; Stelte-Ludwig, B.; Bruggemeier, U.; Vaupel, A.; Gerdes, C. Biphenyls as potent vitronectin receptor antagonists. Bioorg. Med. Chem. Lett., 2002, 12, 205-208.
109. Austel, V.; Himmelsbach, F.; Muller, T.H. Nonpeptidic fibrinogen receptor antagonists. Drugs Future, 1994, 19, 757-764.
110. Corbett, D.F.; Heightman, T.D.; Moss, S.F.; Bromidge, S.M.; Coggon, S.A.; Longley, M.J.; Roa, A.M.; Williams, J.A.; Thomas, D.R. Discovery of a potent and selective 5-ht5A receptor antagonist by highthroughput chemistry. Bioorg. Med. Chem. Lett., 2005, 15, 4014-4048.
111. Soellner, M.B.; Rawis, K.A.; Grundner, C.; Alber, T.; Ellman, J.A. Fragment based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB. J. Am. Chem. Soc., 2007, 129, 9613-9615.
112. Forghieri, M.; Laggner, C.; Paoli, P.; Langer, T.; Manao, G.; Camici, G.; Bondioli, L.; Prati, F.; Costantino, L. Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. Bioorg. Med. Chem., 2009, 17, 2658-2672.
113. Wada, C.K.; Holms, J.H.; Curtin, M.L.; Dai, Y.; Florjancic, A.S.; Garland, R.B.; Guo, Y.; Heyman, H.R.; Stacey, J.R.; Steinman, D.H.; Albert, D.H.; Bouska, J.J.; Elmore, I.N.; Goodfellow, C.L.; Marcotte, P.A.; Tapang, P.; Morgan, D.W.; Michaelides, M.R.; Davidsen, S.K. Phenoxyphenylsulfone Nformylhydroxylamines (Retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J. Med. Chem., 2002, 45, 219-232.
114. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; Joseph, M.K.; Kitada, S.; Korsmeyer, S.J.; Kunzer, A.R.; Letai, A.; Li, C.; Mitten, M.J.; Nettesheim, D.G.; Ng, S.C.; Nimmer, P.M.; O'Connor, J.M.; Oleksijew, A.; Petros, A.M.; Reed, J.C.; Shen, W.; Tahir, S.K.; Thompson, C.B.; Tomaselli, K.J.; Wang, B.; Wendt, M.D.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature, 2005, 435, 677-681.
115. Salata, J.J.; Jurkiewicz, N.K.; Wang, J.; Evans, B.E.; Orme, H.T.; Sanguinetti, M.C. A novel benzodiazepine that activates cardiac slow delayed rectifier Ktttttttttttttcurrents. Mol. Pharmacol., 1998, 53, 220-230.
116. Jurkiewicz, N.K.; Wang, J.; Fermini, B.; Sanguinetti, M.C.; Salata, J.J. Mechanism of action potential prolongation by RP 58866 and its active enantiomer, Terikalant: block of the rapidly activating delayed rectifier K+ current, IKr. Circulation, 1996, 94, 2938-2946.
117. Micale, N.; Vairagoundar, R.; Yakovlev, A.G.; Kozikowski, A.P. Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3. J. Med. Chem., 2004, 47, 6455-6458.
118. Scarborough, R. M; Gretler, D.D. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J. Med. Chem., 2000, 43, 3453-3473.
119. Fisher, M.J.; Gunn, B.; Harms, C.S.; Kline, A.D.; Mullaney, J.T.; Nunes, A.; Scarborough, R.M.; Arfsten, A.E.; Skelton, M.A.; Um, S.L.; Utterbach, B.G.; Jakubowski, J.A. Non-peptide RGD surrogates which mimic a Gly-Asp mm-turn: potent antagonists of platelet glycoprotein IIb-IIIa. J. Med. Chem., 1997, 40, 2085-2101.
120. Marinelli, L.; Lavecchia, A.; Gottschalk, K.E.; Novellino, E.; Kessler, H. Docking studies on vvv3 integrin ligands: pharmacophore refinement and implications for drug design. J. Med. Chem., 2003, 46, 4393-4404.
121. Leonard, D.M. Ras farnesyltransferase: A new therapeutic target. J. Med. Chem., 1997, 40, 2971-2990.
122. Ripka, W.C.; DeLucca G.V.; Bach II A.C.; Pottorf, R.S.; Blaney, J.M. Protein cc-turn mimetics. I. Design, synthesis, and evaluation in model cyclic peptides. Tetrahedron, 1993, 49, 3593-3608.
123. Ripka, W.C.; DeLucca G.V.; Bach II A.C.; Pottorf, R.S.; Blaney, J.M. Protein turn mimetics-II. Design, synthesis, and evaluation in the cyclic peptide gramicidin S. Tetrahedron, 1993, 49, 3609-3628.
124. Dziadulewicz, E.K.; Brown, M.C.; Dunstan, A.R.; Lee, W.; Said, N.B.; Garratt, P.J. The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold. Bioorg. Med. Chem. Lett., 1999, 9, 463-468.
125. Garland, S.L.; Dean, P.M. Design criteria for molecular mimics of fragments of the beta-turn. 1. C alpha atom analysis. J. Comput.-Aided Mol. Des., 1999, 13, 469-483.
126. Chianelli, D.; Kim, Y.C.; Lvovskiy, D.; Webb, T.R. Application of a novel design paradigm to generate general nonpeptide combinatorial scaffolds mimicking beta turns: synthesis of ligands for somatostatin receptors. Bioorg Med. Chem., 2003, 11, 5059-5068.
127. Im, I.; Web, T.R.; Gong, Y.D.; Kim, J.I.; Kim, Y.C. Solid-phase synthesis of tetrahydro-1,4-benzodiazepin-2-one derivatives as a bb-turn peptidomimetic library. J. Comb. Chem., 2004, 6, 207-213.
128. Papageorgiou, C.; Borer, X. A non-peptide ligand for the somatostatin receptor having a benzodiazepinone structure. Bioorg. Med. Chem. Lett., 1996, 6, 267-272.
129. Grasberger, B.L.; Lu, T.; Schubert, C.; Parks, D.J.; Carver, T.E.; Koblish, H.K.; Cummings, M.D.; LaFrance, L.V.; Milkiewicz, K.L.; Calvo, R.R.; Maguire, D.; Lattanze, J.; Franks, C.F.; Zhao, S.; Ramachandren, K.; Bylebyl, G.R.; Zhang, M.; Manthey, C.L.; Petrella, E.C.; Pantoliano, M.W.; Deckman, I.C.; Spurlino, J.C.; Maroney, A.C.; Tomczuk, B.E.; Molloy, C.J.; Bone, R.F. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem., 2005, 48, 909-912.
130. Cummings, M.D.; Schubert, C.; Parks, D.J.; Calvo, R.R.; LaFrance, L.V.; Lattanze, J.; Milkiewicz, K.L.; Lu, T. Substituted 1,4-benzodiazepine-2,5-diones as a helix mimetic antagonists of the HDM2-p53 protein-protein interaction. Chem Biol. Drug Des., 2006, 67, 201-205.
131. Parks, D.J.; LaFrance, L.V.; Calvo, R.R.; Milkiewicz, K.L.; Gupta, V.; Lattanze, J.; Ramachandren, K.; Carver, T.E.; Petrella, E.C.; Cummings, M.D.; Maguire, D.; Grasberger, B.L.; Lu, T. 1,4-benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett., 2005, 15, 765-770.
132. Parks, D.J.; LaFrance, L.V.; Calvo, R.R.; Milkiewicz, K.L.; Marugan, J.J.; Raboisson, P.; Schubert, C.; Koblish, H.K.K.; Zhao, S.Z.; Franks, C.F.; Lattanze, J.; Carver, T.; Cummings, M.D.; Maguire, D.; Grasberger, B.L.; Maroney, A.C.; Lu, T. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg. Med. Chem. Lett., 2006, 16, 3310-3314.
133. Koblish, H.K.; Zhao, S.; Franks, C.F.; Donatelli, R.R.; Tominovich, R.M.; LaFrance, L.V.; Leonard, C.A.; Gushue, J.M.; Parks, D.J.; Calvo, R.R.; Mikiewicz, K.L.; Marugan, J.J.; Raboisson, P.; Cummings, M.D.; Grasberger, B.L.; Johnson, D.L.; Lu, T.; Molloy, C.J.; Maroney, A.C. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther., 2006, 5, 160-169.
134. Fry, D.C. Protein-protein interactions as target for small molecule drug discovery. Biopolymers, 2006, 84, 535-552.
135. Nicolaou, K.C.; Pfefferkorn, J.A.; Roecker, A.J.; Cao, G.Q.; Barluenga, S.; Mitchell, H.J. Natural productlike combinatorial libraries based on privileged structures. 1: general principles and solid-phase synthesis of benzopyrans. J. Am. Chem. Soc., 2000, 122, 9939-9953.
136. Nicolaou, K.C.; Pfefferkorn, J.A.; Mitchell, H.J.; Roecker, A.J.; Barluenga, S.; Cao, G.Q.; Afleck, R.L.; Lillig, J.E. Natural product-like combinatorial libraries based on privileged structures. 2: construction of a 10 000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J. Am. Chem. Soc., 2000, 122, 9954-9967.
137. Nicolaou, K.C.; Pfefferkorn, J.A.; Barluenga, S.; Mitchell, H.J.; Roecker, A.J.; Cao, G.Q. Natural productlike combinatorial libraries based on privileged structures. 3: the "libraries from libraries" principle for diversity enhancement of benzopyran libraries. J. Am. Chem. Soc., 2000, 122, 9968-9976.
138. Nicolaou, K.C.; Roecker, A.J.; Barluenga, S.; Pfefferkorn, J.A.; Cao, G.Q. Natural product-like combinatorial libraries based on privileged structures. 3. The "libraries from libraries" Principle for diversity enhancement of benzopyran libraries. Chem. Biochem., 2001, 6, 460-465.
139. Nicolaou, K.C.; Evans, R.M.; Roecker, A.J.; Hughes, R.; Downes, M.; Pfefferkorn, J.A. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org. Biomol. Chem., 2003, 1, 908-920.
140. Nicolaou, K.C.; Pfefferkorn, J.A.; Schuler, F.; Roecker, A.J.; Cao, J.Q.; Casida, J.E. Combinatorial synthesis of novel and potent inhibitors of NADH:ubiquinone oxidoreductase. Chem. Biol., 2000, 7, 979-992.
141. Midleton, E.; Kandaswami, C. The Flavonoids: Advances in Research since 1986, Harborne, J.B.; Ed.; Chapman and Hall, London, UK, 1993, pp. 619-652.
142. Havsteen, B. Flavonoids, a class of natual products of high pharmacological activity. Biochem. Pharmacol., 1983, 32, 1141-1148.
143. Chetrite, G.S.; Cortes-Prieto, J.; Philippe, J.C.; Wright, F.; Pasqualini, J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Mol. Biol., 2000, 72, 23-27.
144. Burbaum, JJ, Ohlmeyer, M.H.J.; Reader, J.C.; Henderson, I.; Dillard, L.W.; Li, G.; Randle, T.L.; Sigal, N.H.; Chelsky, D. Baldwin, J.J. A paradigm for drug discovery employing encoded combinatorial libraries. Proc. Natl. Acad. Sci. USA., 1995, 92, 6027-6031.
145. Marder, M., Viola, H.; Bacigaluppo, J.A.; Colombo, M.I.; Wasowski, C.; Wolfman, C.; Medina, J.H.; Ruveda, E.A.; Paladini, A.C. Detection of benzodiazepine receptor ligands in small libraries of flavone derivatives synthesized by solution phase combinatorial chemistry. Biochem. Biophys Res. Commun., 1998, 249, 481-485.
146. Harikrishnan, L.; Showatter, H.D.H.; Hollis, D. A novel synthesis of 2,3-disubstituted benzopyran-4-ones and application to the solid phase. Tetrahedron, 2000, 56, 515-519.
147. Ji, X.; Melman, N.; Jacobson, K.A. Interactions of flavonoids and other phytochemicals with adenosine receptors. J. Med. Chem., 1996, 39, 781-788.
148. Conseil, G.; Baubichon-Cortay, H.; Dayan, G.; Jault, J.M.; Barron, D.; Di Pietro, A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP-and steroid-binding sites on mouse Pglycoprotein. Proc. Natl. Acad. Sci. USA., 1998, 95, 9831-9836.
149. Ferriola, P.C.; Cody, V.; Middleton, E. Protein kinase C inhibition by plant flavonoids: kinetic mechanisms and structure-activity relationships. Biochem. Pharmacol., 1989, 38, 1617-1624.
150. Geahlen, R.L.; Koonchanok, N.M.; McLaughlin, J.L. Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds. J. Nat. Prod., 1989, 52, 982-986.
151. Cushman, M.; Zhu, H.; Geahlen, R.L.; Kraker, A.J. Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein tyrosine kinases p56lck, EGFr, and p60v-src. J. Med. Chem., 1994, 37, 3353-3362.
152. McGovern, S.L.; Shoichet, B.K. Kinase inhibitors: not just for kinases anymore. J. Med. Chem., 2003, 46, 1478-1483.
153. McGovern, S.L.; Helfand, B.T.; Feng, B.; Shoichet, B.K. A specific mechanism of non-specific inhibition. J. Med. Chem., 2003, 46, 4265-4272.
154. Naik, R.G.; Kattige, S.L.; Bhat, S.V.; Alreja, B.; deSousa, N.J.; Rupp, R.H. An antiinflammatory and immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: Isolation, structure and total synthesis. Tetrahedron, 1988, 44, 2081-2086.
155. Shapiro, G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor Flavopiridol. Clin. Cancer Res., 2004, 10 (12), 4270-4275.
156. Kim, K.S.; Sack, J.S.; Tokarski, J.S.; Qian, L.; Chao, S.T.; Leith, L.; Kelly, Y.F.; Misra, R.N.; Hunt, J.T.; Kimball, S.D.; Humphreys, W.G.; Wautlet, B.S.; Mulheron, J.G.; Webster, K.R. Thio-and oxoflavopiridols, cyclin-dependent kinase 1-. selective inhibitors: synthesis and biological effects. J. Med. Chem., 2000, 43, 4126-4134.
157. De Azevedo, W.F.; Muller-Dieckmann, H.J.; Schulze Gahmen, U.; Worland, P.J.; Sausville, E.; Kim, S.H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Nat. Acad. Sci. USA., 1996, 93, 2735-2740.
158. Azevedo, W.F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S.H. Inhibition of cyclindependent kinases by purine analogs: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem., 1997, 243, 518-526.
159. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-based generation of a new class of potent Cdk4 inhibitors: New de Novo design strategy and library design. J. Med. Chem., 2001, 44, 4615-4627.
160. Lu, H.; Chang, D.J.; Baratte, B.; Meijer, L.; Schulze-Gahmen, U. Crystal structure of a human cyclindependent kinase 6 complex with a flavonol inhibitor, fisetin. J. Med. Chem., 2005, 48, 737-743.
161. Souers, A.J.; Ellman, J.A. β-Turn mimetic library synthesis: scaffolds and applications. Tetrahedron, 2001, 57, 7431-7448.
162. Hanessian, C.; McNaughton,-Smith, G.; Lombart, H.G.; Lubell, W.D. Design and synthesis of conformationally constrained amino acids as versatile scaffolds and peptide mimetics. Tetrahedron, 1997, 53, 12789-12854.
163. Stradley, S.J.; Rizo, J.; Bruch, M.D.; Stroup, A.N.; Gierasch, L.M. Cyclic pentapeptides as models for reverse turns: determination of the equilibrium distribution between type I and type II conformations of Pro-Asn and Pro-Ala PP-turns. Biopolymers, 1990, 29, 263-287.
164. Souers, A.J.; Virgilio, A.A.; Rosenquist, A.; Fenuik, W.; Ellman, J.A. Identification of a potent heterocyclic ligand to somatostatin receptor subtype 5 by the synthesis and screening of ll-turn mimetic libraries. J. Am. Chem. Soc., 1999, 121, 1817-1825.
165. Souers, A.J.; Virgilio, A.A.; Schurer, S.S.; Ellmann, J.A. Novel inhibitors of 4441 integrin receptor interactions through library synthesis and screening. Bioorg. Med. Chem. Lett., 1998, 8, 2297-2302.
166. Horton, D.A.; Bourne, G.T.; Smythe, M.L. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. J. Comp. Aided Mol. Drug Des., 2002, 16, 415-431.
167. Li, J.; Murray, C.W.; Waszkowycz, B.; Young, S.C. Targeted molecular diversity in drug discovery: integration of structure-based design and combinatorial chemistry. Drug Discov. Today, 1998, 3, 105-118.
168. del Fresno, M.; Fernandez-Forner, D.; Miralpeix, M.; Segarra, V.; Ryder, H.; Royo, M.; Albericio, F. Combinatorial approaches towards the discovery of new tryptase inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 1659-1664.
169. Schaschke, N.; Dominik, A.; Mastchiner, G.; Sommerhoff, C.P. Bivalent inhibition of ii-Tryptase: distance scan of neighboring subunits by dibasic inhibitors. Bioorg. Med. Chem. Lett., 2002, 12, 985-988.
170. Royo, M.; Van Den Nest, W.; del Fresno, M.; Frieden, A.; Yahalom, D.; Rosenblatt, M.; Chorev, M.; Albericio, F. olid-phase syntheses of constrained RGD scaffolds and their binding to the FFvvv3 integrin receptor. Tetrahedron Lett., 2001, 42, 7387-7391.
171. Smith, A.B.; Hirschmann, R.; Pasternak, A.; Akaishi, R.; Guzman, M.C.; Jones, D.R.; Keenan, T.P.; Sprengler, P.A.; Darke, P.L.; Emini, E.A.; Holloway, M.K.; Schleif, W.A. Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin: evidence for improved transport. J. Med. Chem., 1994, 37, 215-218.
172. Smith, A.B.; Hirschmann, R.; Pasternack, A.; Yao, W.; Sprengeler, P.A.; Holloway, M.K.; Kuo, L.C.; Chen, Z.; Darke, P.L.; Schleif, W.A. An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex. J. Med. Chem., 1997, 40, 2440-2444.
173. Smith, A.B.; Hirschmann, R.; Pasternak, A.; Guzman, M.C.; Yokoyama, A.; Sprengeler, P.A.; Darke, P.L.; Emini, E.A.; Schleif, W.A. Pyrrolinone-based HIV protease inhibitors: design, synthesis, and antiviral activity: Evidence for improved transport. J. Am. Chem. Soc., 1995, 117, 11113-11123.
174. Smith, A.B.; Akaishi, R.; Jones, D.R.; Keenan, T.P.; Guzman, M.C.; Holcomb, R.C.; Sprengeler, P.A.; Wood, J.L.; Hirschmann, R.; Holloway, M.K. Design and synthesis of nonpeptide peptidomimetic inhibitors of renin. Biopolymers, 1995, 37, 29-53.
175. Smith, A.B.; Nittoli, T.; Sprengeler, P.A.; Duan, J.J.-W.; Liu, R.-Q.; Hirschmann, R.F. Design, synthesis, and evaluation of a pyrrolinone-based matrix metalloprotease inhibitor. Org. Lett., 2000, 2, 3809-3812.
176. Smith, A.B.; Benowitz, A.B.; Sprengeler, P.A.; Barbosa, J.; Guzman, M.C.; Hirschmann, R.; Schweiger, E.J.; Bolin, D.R.; Nagy, Z.; Campbell, R.M.; Cox, D.C.; Olson, G.L. Design and synthesis of a competent pyrrolinone-peptide hybrid ligand for the Class II Major Histocompatibility Complex Protein HLA-DR1. J. Am. Chem. Soc., 1999, 121, 9286-9298.
177. Smith, A.; Charnley, A.K.; Mesaros, E.F.; Kikuchi, O.; Wang, W.; Benowitz, A.; Chu, C.L.; Feng, J.J.; Chen, K.H.; Lin, A.; Cheng, F.C.; Taylor, L.; Hirschmann, R. Design, synthesis, and binding affinities of pyrrolinone-based somatostatin mimetics. Org. Lett., 2005, 7, 399-402.
178. Smith, A.B.; Favor, D.A.; Sprengeler, P.A.; Guzman, M.C.; Carroll, P-J.; Furst, G.T.; Hirschmann, R. Molecular modeling, synthesis, and structures of N-methylated 3,5-linked pyrrolin-4-ones toward the creation of a privileged nonpeptide scaffold. Bioorg. Med. Chem., 1999, 7, 9-22.
179. Burke, M.D.; Schreiber, S.L. A planning strategy for diversity-oriented synthesis. Angew. Chem. Int. Ed. Engl., 2004, 43, 46-58.
180. Burke, M.D.; Berger, E.M.; Schreiber, S.L. Generating diverse skeletons of small molecules combinatorially. Science, 2003, 302, 613-618.
181. Schreiber, S.L. Molecular diversity by design. Nature, 2009, 457, 153-154.